glp 1 agonist with dpp 4 inhibitor DPP4 Inhibitors vs GLP-1 Agonists | June 2021 | Clinical Corner Mechanisms of dipeptidyl peptidase‐4 (DPP‐4)
Description
Your provider will guide the transition
The gliptins do not significantly modify the pharmacokinetic profile and exposure of other medicines, and vice versa
Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
However, in SURPASS-5, individuals on a background of insulin glargine and tirzepatide reported serious hypoglycemia (19%) more than individuals on a background of insulin glargine and placebo (13%) [14]
[DOI] [PMC free article] [PubMed] [Google Scholar] 119.Gao Q., Jia Y., Yang G., Zhang X., Boddu P.C., Petersen B., Narsingam S., Zhu Y.J., Thimmapaya B., Kanwar Y.S., et al
Fact sheet no
